10/09/13 -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, today presented additional results from HVTN 205, a multicenter, randomized Phase 2a trial evaluating the safety and ...
http://www.freshnews.com/news/854556/geovax-dna-mva-vaccine-elicits-sustained-antibody-responses-hiv-
http://www.freshnews.com/news/854556/geovax-dna-mva-vaccine-elicits-sustained-antibody-responses-hiv-
No comments:
Post a Comment